Inhibition of BRCA1 and BRCA2 gene expression suggested a synergistic cytotoxic effect with PARP1 inhibitor based on previous findings in breast cancer with mutation of BRCA1 or BRCA2 [44]. Here, BRCA2 is linked to breast carcinoma.